Measurable residual disease in chronic lymphocytic leukemia. Where do we stand?

Leukemia. 2023 Dec;37(12):2339-2342. doi: 10.1038/s41375-023-02066-w. Epub 2023 Oct 14.

Authors

Ilaria Del Giudice¹, Robin Foà²

Affiliations

¹ Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy. ilaria.delgiudice@uniroma1.it.
² Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy. rfoa@bce.uniroma1.it.

PMID: 37838758
DOI: 10.1038/s41375-023-02066-w

No abstract available

Publication types

Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Neoplasm, Residual / drug therapy